BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Dec 6, 2020
Product Development

Two incentives that could open the floodgates to drug repositioning for COVID-19: Guest Commentary

With excitement of the encouraging data on COVID-19 prophylactic vaccines, let’s not forget the infection rate and mortality are higher than ever, and treatment options are limited. One of the missed opportunities...
BioCentury | Nov 19, 2020
Product Development

Lucira’s at-home COVID-19 LAMP test breaks barrier, not dam

The first FDA-authorized at-home COVID-19 test makes it possible for symptomatic patients to get a rapid diagnosis while isolating at home, but is unlikely to open the floodgates to routine self-screening....
BioCentury | May 29, 2020
Politics, Policy & Law

Proposed CMS rule for CAR Ts marks progress in reimbursing new technologies

It’s been four years since the first CAR T cell therapies were approved and inadequate reimbursement is still a barrier to access in the U.S. A new payment rule proposed by CMS aims to change...
BioCentury | Oct 21, 2019
Emerging Company Profile

Inscopix: scoping out better preclinical models via live brain imaging

...Inc. Number of employees: 60 Funds raised: $11.5 million Investors: Playground Ventures, AME Cloud Ventures, Floodgate...
BioCentury | Oct 28, 2017
Finance

Big cap bloodletting

Performance of biotechs valued at over $10 billion was already dwindling throughout 2017 before a flood of disappointing earnings began to roll in for several of the largest companies. In the days since Oct. 19,...
BioCentury | Sep 26, 2016
Regulation

Not so fast

FDA documents concerning the review of Exondys 51 eteplirsen to treat DMD show that the chorus keening that the approval opens the floodgates for companies to combine shoddy, underpowered studies with patient activism to gain...
BioCentury | Sep 5, 2016
Financial News

Inscopix completes venture financing

...Date completed: 2016-08-25 Type: Venture financing Raised: $10 million Investors: Playground Ventures; AME Cloud Ventures; Floodgate WIR...
BioCentury | May 9, 2016
Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...
BioCentury | Jan 19, 2015
Strategy

Partitioning HCV

Gilead Sciences Inc. and AbbVie Inc. continue to vie for preferred coverage of their HCV drugs in the U.S. private payer market, and Gilead is out to an early lead when it comes to total...
Items per page:
1 - 10 of 30
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Dec 6, 2020
Product Development

Two incentives that could open the floodgates to drug repositioning for COVID-19: Guest Commentary

With excitement of the encouraging data on COVID-19 prophylactic vaccines, let’s not forget the infection rate and mortality are higher than ever, and treatment options are limited. One of the missed opportunities...
BioCentury | Nov 19, 2020
Product Development

Lucira’s at-home COVID-19 LAMP test breaks barrier, not dam

The first FDA-authorized at-home COVID-19 test makes it possible for symptomatic patients to get a rapid diagnosis while isolating at home, but is unlikely to open the floodgates to routine self-screening....
BioCentury | May 29, 2020
Politics, Policy & Law

Proposed CMS rule for CAR Ts marks progress in reimbursing new technologies

It’s been four years since the first CAR T cell therapies were approved and inadequate reimbursement is still a barrier to access in the U.S. A new payment rule proposed by CMS aims to change...
BioCentury | Oct 21, 2019
Emerging Company Profile

Inscopix: scoping out better preclinical models via live brain imaging

...Inc. Number of employees: 60 Funds raised: $11.5 million Investors: Playground Ventures, AME Cloud Ventures, Floodgate...
BioCentury | Oct 28, 2017
Finance

Big cap bloodletting

Performance of biotechs valued at over $10 billion was already dwindling throughout 2017 before a flood of disappointing earnings began to roll in for several of the largest companies. In the days since Oct. 19,...
BioCentury | Sep 26, 2016
Regulation

Not so fast

FDA documents concerning the review of Exondys 51 eteplirsen to treat DMD show that the chorus keening that the approval opens the floodgates for companies to combine shoddy, underpowered studies with patient activism to gain...
BioCentury | Sep 5, 2016
Financial News

Inscopix completes venture financing

...Date completed: 2016-08-25 Type: Venture financing Raised: $10 million Investors: Playground Ventures; AME Cloud Ventures; Floodgate WIR...
BioCentury | May 9, 2016
Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...
BioCentury | Jan 19, 2015
Strategy

Partitioning HCV

Gilead Sciences Inc. and AbbVie Inc. continue to vie for preferred coverage of their HCV drugs in the U.S. private payer market, and Gilead is out to an early lead when it comes to total...
Items per page:
1 - 10 of 30